Pancreatic cancer: Advances and challenges
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
Therapeutic targeting of tumour myeloid cells
ST Barry, DI Gabrilovich, OJ Sansom… - Nature Reviews …, 2023 - nature.com
Myeloid cells are pivotal within the immunosuppressive tumour microenvironment. The
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …
accumulation of tumour-modified myeloid cells derived from monocytes or neutrophils …
Translational advances in pancreatic ductal adenocarcinoma therapy
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
[HTML][HTML] Ordered and deterministic cancer genome evolution after p53 loss
Although p53 inactivation promotes genomic instability and presents a route to malignancy
for more than half of all human cancers,, the patterns through which heterogenous TP53 …
for more than half of all human cancers,, the patterns through which heterogenous TP53 …
Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment
Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Develo** novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …
short time frame at an affordable cost. While this technology has been widely implemented …
Pancreatic cancer
Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …
The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives
S Wang, Y Zheng, F Yang, L Zhu, XQ Zhu… - Signal transduction and …, 2021 - nature.com
Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …
correspondence between disease mortality and incidence. Furthermore, it is usually …